May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Resource Utilization and Direct Medical Costs to Medicare for Beneficiaries With Incident Diabetic Macular Edema
Author Affiliations & Notes
  • L. Curtis
    Ctr for Clinical & Genetic Economics, Duke Clinical Research Institute, Durham, North Carolina
    Medicine,
    Duke University School of Medicine, Durham, North Carolina
  • A. Shea
    Ctr for Clinical & Genetic Economics, Duke Clinical Research Institute, Durham, North Carolina
  • B. Hammill
    Ctr for Clinical & Genetic Economics, Duke Clinical Research Institute, Durham, North Carolina
  • J. Kowalski
    Global Health Outcomes Research, Allergan, Inc, Irvine, California
  • A. Ravelo
    Global Health Outcomes Research, Allergan, Inc, Irvine, California
  • P. Lee
    Department of Ophthalmology,
    Duke University School of Medicine, Durham, North Carolina
  • K. Schulman
    Ctr for Clinical & Genetic Economics, Duke Clinical Research Institute, Durham, North Carolina
    Medicine,
    Duke University School of Medicine, Durham, North Carolina
  • Footnotes
    Commercial Relationships  L. Curtis, Allergan, Inc., F; A. Shea, None; B. Hammill, None; J. Kowalski, Allergan, Inc., E; A. Ravelo, Allergan, Inc., E; P. Lee, Allergan, Inc., F; K. Schulman, Allergan, Inc., F.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3757. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Curtis, A. Shea, B. Hammill, J. Kowalski, A. Ravelo, P. Lee, K. Schulman; Resource Utilization and Direct Medical Costs to Medicare for Beneficiaries With Incident Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3757. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To examine trends in resource utilization and the impact of incident diabetic macular edema (DME) on 1- and 3-year total direct medical costs in elderly patients with diabetes.

Methods: : We used a nationally representative 5% sample of Medicare beneficiaries from 2000-2004 to identify incident DME patients, and a diabetic control cohort with no history of retinal disease. We summed Medicare reimbursement amounts for all inpatient, outpatient, home health, skilled nursing, hospice, durable medical equipment, and professional service claims and applied generalized linear models to estimate the effect of DME on 1- and 3-year costs. We also examined 1-year resource utilization.

Results: : Both one- and three-year mean total direct medical costs were approximately 25% higher among DME cases than diabetic controls. In univariate analyses, DME was associated with 34% higher 1-year costs and 33% higher 3-year costs. Controlling for age, sex, race, geographic region, and baseline comorbid diagnoses, DME was still a significant independent predictor of total medical costs at 1 and 3 years. In multivariable analyses, DME was associated with 25% higher 1-year costs and 27% higher 3-year costs. Significant shifts in the use of DME treatment modalities were observed over time. From 2000 to 2004, treatment of incident DME with intravitreal injection increased from 1% to 13% of patients; treatment with OCT increased from 2.5% to more than 40%. The use of laser photocoagulation decreased over time.

Conclusions: : After controlling for demographic variables and baseline comorbidities, new onset macular edema was a significant independent predictor of total medical costs at both 1 and 3 years. Diagnostic and treatment modalities used for DME have changed significantly over time.

Keywords: diabetic retinopathy • aging 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×